Triple therapy for type 2 diabetes and kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had type 2 diabetes for at least 6 months
- Your kidney function is reduced (eGFR between 25 and 90) and you have some protein in your urine, OR your kidney function is normal but you have a lot of protein in your urine
- Your blood potassium level is below 4.8 mmol/L
- You are already taking an SGLT2i medication (like dapagliflozin or empagliflozin) for at least 4 weeks
- You are taking an ACE inhibitor or ARB at the highest dose you can tolerate without side effects
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
This study tests whether adding dulaglutide (a weekly injection) to two medications you may already be taking—an SGLT2 inhibitor and finerenone—helps protect your kidneys and controls blood sugar better in people with type 2 diabetes and chronic kidney disease.
This trial is testing a medication called finerenone to see how well it helps people with type 2 diabetes who also have chronic kidney disease. Researchers are looking at how the drug affects kidney function and related health factors.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This study tests new treatments to protect the heart and kidneys in people with long-standing type 1 diabetes. It aims to prevent or slow down complications like heart failure and kidney damage.
This observational study tracks how well finerenone (a kidney-protective medication) works in adults with type 2 diabetes and chronic kidney disease in Spain. Researchers will measure changes in kidney function and disease risk over time to better understand the medication's real-world benefits.
Hear when a new Patients With Type 2 Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.